SCHEMBL5054070

SCHEMBL5054070

N#Cc1ccc2c(-c3cc4c(CN5CCC(N(C6CC6)S(=O)(=O)c6ccc(Cl)cc6)CC5)cccc4[nH]3)n[nH]c2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 5/20 0.48
CDK7 P50613 3/20 0.43
ITK Q08881 3/20 0.43
DRD2 P14416 3/20 0.37
DRD4 P21917 3/20 0.37
DRD3 P35462 3/20 0.37
PSEN1 P49768 1/20 0.34
PSEN2 P49810 1/20 0.34
APH1B Q8WW43 1/20 0.34
NCSTN Q92542 1/20 0.34
APH1A Q96BI3 1/20 0.34
PSENEN Q9NZ42 1/20 0.34
MAPK1 P28482 1/20 0.34
AGER Q15109 1/20 0.34
NR1I2 O75469 2/20 0.33
CACNA1B Q00975 2/20 0.33
MAPT P10636 1/20 0.33
CCNT1 O60563 1/20 0.33
CCNK O75909 1/20 0.33
CCNE1 P24864 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4161043 0.81 CHEK1 (0.70) CHEK1CDK7ITKDRD2DRD4
SCHEMBL5061262 0.81 CHEK1 (0.58) CHEK1CDK7ITKDRD2DRD4
SCHEMBL5054046 0.81 CHEK1 (0.56) CHEK1CDK7ITKDRD2DRD4
SCHEMBL5058960 0.80 CHEK1 (0.52) CHEK1CDK7ITKDRD2DRD4
SCHEMBL5055574 0.79 ITK (0.56) CHEK1CDK7ITKDRD2DRD4
SCHEMBL27708371 0.78 ITK (0.53) CHEK1CDK7ITKDRD2DRD4
SCHEMBL5054010 0.78 CHEK1 (0.68) CHEK1CDK7ITKDRD2DRD4
SCHEMBL5051859 0.77 CHEK1 (0.48) CHEK1CDK7ITKMAPK1CCNT1
SCHEMBL5054096 0.77 CHEK1 (0.70) CHEK1CDK7ITK
SCHEMBL5054163 0.76 ITK (0.53) CHEK1CDK7ITKDRD2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080004259-A1 Inhibitors of Checkpoint Kinases MERCK & CO., INC. 2008-01-03 US claimed
EP-1851203-A2 INHIBITORS OF CHECKPOINT KINASES Merck & Co., Inc. (US) 2007-11-07 EP claimed
WO-2006086255-A2 INHIBITORS OF CHECKPOINT KINASES MERCK & CO., INC. (US) 2006-08-17 WO claimed
US-20080004259-A1 Inhibitors of Checkpoint Kinases MERCK & CO., INC. 2008-01-03 US disclosed
EP-1851203-A2 INHIBITORS OF CHECKPOINT KINASES Merck & Co., Inc. (US) 2007-11-07 EP disclosed
WO-2006086255-A2 INHIBITORS OF CHECKPOINT KINASES MERCK & CO., INC. (US) 2006-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004259-A1 Inhibitors of Checkpoint Kinases CHEK1, CHEK2, BUB1B CHEK1 1/4885CDK7 43/4885ITK 493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.